Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Cited by 138 Publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Stem Cell Reports, 2019, 10.1016/j.stemcr.2019.08.005

PubMed: 31522974 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7617

PubMed: 31110200 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )
J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )

Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )
Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )

Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )

Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )

Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )

J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1275-86

PubMed: 25983018 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )
Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )

Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):3249-3256

PubMed: 25975261 ( click the link to review the publication )

Int J Clin Exp Pathol, 2015, 8(7):7818-24

PubMed: 26339346 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Exp Cell Res, 2014, 328(1):20-31

PubMed: 25128812 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )
Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Head Neck, 2014, 36(3):375-84

PubMed: 23729178 ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

Neoplasia, 2013, 15(11):1272-81

PubMed: 24339739 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Int J Oncol, 2013, 43(6):2064-72

PubMed: 24126464 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(1):35-44

PubMed: 23712327 ( click the link to review the publication )

Pharmgenomics Pers Med, 2013, 6:63-72

PubMed: 24019750 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )
Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Targets

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. ^[1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. ^[3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	M1jvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUfSbG04PzJiaB?=	MoHiSG1UVw>?	NGWyb4FKSzVyPUCuNFAxODdizszN	M1vYeVE4QTV4MEiw
K562	M{C4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXi3NkBp	M3SxcGROW09?	MoezTWM2OD1yLkCwNUDPxE1?	Ml6zNVc6PTZyOEC=
M07e	NYL6SXY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYDmeGFWPzJiaB?=	M{TVdmROW09?	MVfJR\|UxRTBwMECxNkDPxE1?	MlPWNVc6PTZyOEC=
ALL3	MlK2R5l1d3SxeHnjJGF{e2G7	MnHFNE4y\|ryP	M2jVcFczKGh?	M4ftN2ROW09?	MUTJR\|UxRTBwMECwOEDPxE1?	NXvsN2dTOTl6OEm1OFA>
CML	NWH2NYQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2\ofFIxKG2rbh?=	NEXSfWlFVVOR	M1\XfmlEPTB;MD6wNFEh\|ryP	M2fwOFE6OjF7MEG2
BA/F3	NXXYUWpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIf5U4M4OiCq	NVPNTop[TE2VTx?=	MWfJR\|UxRTZwNUi5JO69VQ>?	Mni1NlMxQDh4NES=
BA/F3	NVfXcWdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIPBZYU4OiCq	NFrVOWlFVVOR	NXy1ZVR6UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0>	MmfmNlMxQDh4NES=
BA/F3	M2rHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF3JSpg4OiCq	MVvEUXNQ	M1vtb2lv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO\|aX7nJJdqdGRidInw[UBD[3JvQXLsJJdqfGhiSVO1NEBw\iByLkCwOFXPxE1?	MkPuNlMxQDh4NES=
BA/F3	MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEnlZXY4OiCq	NGT0W2tFVVOR	M1PicGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO\|aX7nJGJkei2DYnygWFMyPUlibYX0ZY51KHerdHigTWM2OCCxZjCxMlcyPM7:TR?=	MnvQNlMxQDh4NES=
BA/F3	NEjDdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2HvcVczKGh?	NYDsNVlnTE2VTx?=	NYfFXlVJUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRkS4OnMhdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxODoQvF2=	NID2Z2czOzNyMUewNy=>
BA/F3	NVjrdWpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4DzZVczKGh?	M4TDemROW09?	NHK0S\|RKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFA{Os7:TR?=	NHPYWmczOzNyMUewNy=>
BA/F3	NX;IRo1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M33ldVczKGh?	MoXxSG1UVw>?	NYDyenFUUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiR{K1NGUhdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxPTIQvF2=	M17VPVI{OzBzN{Cz
BA/F3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2rzW\|czKGh?	NXH4cFIzTE2VTx?=	NX\sWFJGUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?=	Ml3VNlM{ODF5MEO=
BA/F3	Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEmw[Y44OiCq	NH;YTnJFVVOR	Mln0TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1?	M{\WSVI{OzBzN{Cz
BA/F3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYC3NkBp	MUDEUXNQ	NVvQZWh{UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDCR3IuSUKOIHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVnPxE1?	M3TsTFI{OzBzN{Cz
BA/F3	NVXlbo9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFfPN4w4OiCq	MXjEUXNQ	MW\JcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV\|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>?	NX\xOmJ1OjN\|MEG3NFM>
BA/F3	MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4j1WlczKGh?	NUnaWXhITE2VTx?=	MXvJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBVOzF3STDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDNwNt88US=>	M4HTOlI{OzBzN{Cz
BA/F3	NWnVSVRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmXRO\|IhcA>?	M33XfGROW09?	Mm\PTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42\|ryP	NUKzbpBoOjN\|MEG3NFM>
T cell	MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF7yRXY4OiCq	MWDEUXNQ	M3;1eWlvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO	Mnr0NVcyPTR3MUK=
WiDr	M1;aUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1TkXVczKGh?	MnPuSG1UVw>?	NUTB[4hYUUN3ME2wMlA2OiEQvF2=	MVWxOVYyPTVzMh?=
PC3	NYDVPGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX[3NkBp	MVzEUXNQ	Mli5TWM2OD1yLkCwPVQh\|ryP	MWexOVYyPTVzMh?=
MDA-MB-231	NHf6c4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkjLO\|IhcA>?	Ml\OSG1UVw>?	MVvJR\|UxRTBwMEGyJO69VQ>?	NX3sXHdiOTV4MUW1NVI>
Hs578T	NEjmNWNEgXSxdH;4bYMhSXO\|YYm=		NGrHcIc4OiCq	MVPEUXNQ	MlrrS2k2OD1yLkCzJO69VQ>?	NVzaVnprOjRyMUWzNlc>
HMEC	MUXDfZRwfG:6aXOgRZN{[Xl?		M2rhbFczKGh?	MkLtSG1UVw>?	NIjj[FdIUTVyPUGuPEDPxE1?	M1LhVVI1ODF3M{K3
DU145	NYPOZ3pQS3m2b4TvfIlkKEG\|c3H5		MmTYO\|IhcA>?	MYfEUXNQ	NGjJbWZIUTVyPUCuNVYh\|ryP	MViyOFAyPTN{Nx?=
U251	MYnDfZRwfG:6aXOgRZN{[Xl?		MV63NkBp	M4SzV2ROW09?	M4DJUWdKPTB;Mj64NUDPxE1?	MYqyOFAyPTN{Nx?=
NCI60	NYrm[\|JmS3m2b4TvfIlkKEG\|c3H5		NXLHSmxPPzJiaB?=	M{WxdGROW09?	NHnlTolIUTVyPUWuO{DPxE1?	MW[yOFAyPTN{Nx?=
MALME-3M	MWPDfZRwfG:6aXOgRZN{[Xl?		M1;lZVczKGh?	Mmn3SG1UVw>?	MWrHTVUxRTZwNkGg{txO	MXWyOFAyPTN{Nx?=
KM12	MnXJR5l1d3SxeHnjJGF{e2G7		MnLrO\|IhcA>?	MU\EUXNQ	NGfEW4xIUTVyPUeuOFQh\|ryP	MWqyOFAyPTN{Nx?=
SW620	NHzuPFlEgXSxdH;4bYMhSXO\|YYm=		NUT4SWE1PzJiaB?=	NI\jRVZFVVOR	MknKS2k2OD16LkSzJO69VQ>?	Ml60NlQxOTV\|Mke=
RXF 393NL	NWr1dGZXS3m2b4TvfIlkKEG\|c3H5		NH75U4U1KGSjeYO=	M1jVcmROW09?	NX\DcJBrUUN3ME2wMlAzOTdizszN	MYGyN\|I2OzB5NB?=
LXFA 983L	M{K2cGN6fG:2b4jpZ{BCe3OjeR?=		M1rGfVQh\GG7cx?=	NETUc\|FFVVOR	M2PvVWlEPTB;MD6wOVY2KM7:TR?=	MXyyN\|I2OzB5NB?=
PRXF DU145	NHLOVW9EgXSxdH;4bYMhSXO\|YYm=		NELPN\|Y1KGSjeYO=	NGHhb2xFVVOR	M2LQZmlEPTB;MD6wOlI{KM7:TR?=	NYLsVXZjOjN{NUOwO\|Q>
PAXF 1657L	NEK4V\|ZEgXSxdH;4bYMhSXO\|YYm=		Mki4OEBl[Xm\|	M4rPVWROW09?	MmPxTWM2OD1yLkGyNUDPxE1?	M4DvblI{OjV\|MEe0
CXF 1103L	NIfES2REgXSxdH;4bYMhSXO\|YYm=		MkTJOEBl[Xm\|	NX7Ie49XTE2VTx?=	M{LlRWlEPTB;ND6zOkDPxE1?	MlvkNlMzPTNyN{S=
GXF251L	NILC[VdEgXSxdH;4bYMhSXO\|YYm=		MoTpOEBl[Xm\|	MV;EUXNQ	MWXJR\|UxRTJwMkWg{txO	M3nvW\|I{OjV\|MEe0
NCI-H23	NX3GWYx2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUDjZW02PzJiaB?=	M{HWRWROW09?	MkK3TWM2OD1{LkK3JO69VQ>?	MXOyN\|UzOTB{MB?=
HCT116	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHTMRZc4OiCq	M2ryZmROW09?	MkP5TWM2OD1{LkOg{txO	NH\XXo8zOzV{MUCyNC=>
MCF7	NUHYeWh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVrEeopxPzJiaB?=	M1TyTGROW09?	MoS3TWM2OD1{LkW3JO69VQ>?	NULRXosyOjN3MkGwNlA>
NCI-H460	NWnRfVE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUK3NkBp	NVXjfY1ETE2VTx?=	MUjJR\|UxRThwOUmg{txO	MV:yN\|UzOTB{MB?=
DLD1	M2P1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkPTO\|IhcA>?	NXzTfJpsTE2VTx?=	NXTOdIUxUUN3ME20MlYh\|ryP	MlHBNlM2Pjd7NkC=
NCI-H661	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4TncVczKGh?	NH3DSIZFVVOR	NWLkNYN4UUN3ME23Mlgh\|ryP	NEK0dlQzOzV4N{m2NC=>
A549	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH\TfIg4OiCq	NVHkdZVNTE2VTx?=	M2XZWWlEPTB;OD6yJO69VQ>?	M2j2eFI{PTZ5OU[w
U937	MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnvLO\|IhcA>?	M2DRT2ROW09?	M1KwVWlEPTB;MUKuNkDPxE1?	NHjpcXUzOzV4N{m2NC=>
HEK293	Ml7KSpVv[3Srb36gRZN{[Xl?	NWrMVFQ5OTEEoN88US=>		NYK2VXh6TE2VTx?=	Ml\GTY5lfWOnczDibY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIH\1cIwudGWwZ4ToJGhqey22YXfn[YQhVXm2MTDrbY5ie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC5aYToJGlEPTBib3[gNE4xPjQQvF2=	M3Xu[lIzPzdyNkGw
HUVEC	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHjNE4yPcLizszN	NH\4cW04OiCq	MoXISG1UVw>?	MonnTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDheEAxNjF3IIXN	MXeyNlg2Ozl7Mx?=
HUVEC	MnrzSpVv[3Srb36gRZN{[Xl?	NV\LPXlQOTYEoN88US=>	NGSwblU4OiCq	NU\iR3pmTE2VTx?=	M2T3ZWlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC\|bX;veIghdXW\|Y3zlJINmdGy\|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO	NHvkXZczOjh3M{m5Ny=>
Plasmodium falciparum	M1vse2Z2dmO2aX;uJGF{e2G7	MnfiNVDDqM7:TR?=	NWHnWHhvOTVibXnu	MoW3SG1UVw>?	MoTKTY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txO	NF\PdpYzPDV3MEOzNC=>
PC3	M4T5[GZ2dmO2aX;uJGF{e2G7	MWmwMlEh\|ryP	NH3Xbok2KGh?	M1XwOmROW09?	NEjYNZJKdmirYnn0d{BpfW2jbjDQR\|Mh[2WubDDh[Ihme2mxbjDheEAyODBibl2=	NYnObHZCOTl2NkK5O\|U>
DU145	NECzTJNHfW6ldHnvckBCe3OjeR?=	MkPPNE4yKM7:TR?=	M1LG[VUhcA>?	MVPEUXNQ	MUDJcohq[mm2czDoeY1idiCGVUG0OUBk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?=	NYXqcnZ4OTl2NkK5O\|U>
PC3	NHLFT2RMcW6jc3WgRZN{[Xl?	NGP1cXcxNjFizszN	M1nSUFUhcA>?	NWnYOIJwTE2VTx?=	Mki1TY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?=	NWXxXIFYOTl2NkK5O\|U>
DU145	MYfLbY5ie2ViQYPzZZk>	NUL5SYZjOC5zIN88US=>	MUi1JIg>	M2rSSWROW09?	MWjJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2=	MWGxPVQ3Ojl5NR?=
PC3	NXvXOXcyU2mwYYPlJGF{e2G7	MnnBNE4yKM7:TR?=	M3X6OVUhcA>?	MUjEUXNQ	MXrJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0>	M1;oUFE6PDZ{OUe1
DU145	MlXiT4lv[XOnIFHzd4F6	MlyzNE4yKM7:TR?=	MnruOUBp	NV;tU2NpTE2VTx?=	NUPuUXZ1UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2=	M1vmSlE6PDZ{OUe1
Huh7	MY\BcpRqfmm{YXygRZN{[Xl?	MkW5Nk42KM7:TR?=	Mn\iOEBl[Xm\|	M4LKbmROW09?	NYP4VZgzUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN	MnnpNVc{PjB4N{[=
C6/36	MVnBcpRqfmm{YXygRZN{[Xl?	M2fiTVIvPSEQvF2=	MmHlOEBl[Xm\|	M{Hjb2ROW09?	NF\3Vo1KdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGG\|aXHuJJRq\2W{IH3vd5F2cXSxIFO2M\|M3KGOnbHzzJIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP	MWmxO\|M3ODZ5Nh?=
U937	M2fiRmZ2dmO2aX;uJGF{e2G7	MWKxJO69VQ>?	MoG5NUBp	M1XmbWROW09?	M3fNdHJm\HWlZYOgZoF{[WxiVF7GZYxxcGFicnXs[YF{\SCrbjDoeY1idiCXOUO3JINmdGy\|	NXrF[Jc4OTd4OESwPVk>
U937	NWW0dHFVTnWwY4Tpc44hSXO\|YYm=	M4fqdlEh\|ryP	NUnEeYFFOSCq	MnH4SG1UVw>?	NVzBNXY3WmWmdXPld{BNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN?	NFvxRmIyPzZ6NEC5PS=>
murine mast cell	MnrXSpVv[3Srb36gRZN{[Xl?	M1\pcVEh\|ryP	MXKyOEBp	NUHDVZBsTE2VTx?=	NXr4RmpTUW6qaXLpeJMh[W62aXflck1qdmS3Y3XkJGlNPiC\|ZXPy[ZRqd25iaX6gTYdGKHC{aX3l[EBud3W\|ZTDtZZN1KGOnbHzzJIF1KDFidV2=	MlGwNVc3QDRyOUm=
BV-173	NFni[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoruTWM2OD1yLkCwNFAxODFyOTFOwG0>	NVfxSoc2W0GQR1XS
K-562	M33JbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3zXYFYUUN3ME2wMlAxODByMEK2OkDPxE1?	MoTYV2FPT0WU
BL-70	MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmn4TWM2OD1yLkCwNFAxODh{MjFOwG0>	MX;TRW5ITVJ?
EM-2	MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;Xe4lKSzVyPUCuNFAxODBzMEig{txO	NYfiNHBLW0GQR1XS
LAMA-84	NXrKb2NzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{noXGlEPTB;MD6wNFAxODN{MTFOwG0>	MYLTRW5ITVJ?
MEG-01	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\1eodKSzVyPUCuNFAxODB7ODFOwG0>	NXfQRmVQW0GQR1XS
EoL-1-cell	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUW3cpg2UUN3ME2wMlAxODBzM{Gg{txO	Mm\wV2FPT0WU
CTV-1	M364OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXQNnd6UUN3ME2wMlAxODB2MESg{txO	M4\scHNCVkeHUh?=
TE-15	NIq0NJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLSXVdxUUN3ME2wMlAxPTh7IN88US=>	MWjTRW5ITVJ?
NOS-1	NF25fWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHaWJBKSzVyPUCuNFA3OTNizszN	M{nwW3NCVkeHUh?=
D-336MG	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fiVGlEPTB;MD6wNFY{KM7:TR?=	MVXTRW5ITVJ?
LB1047-RCC	M1ziNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTBwMEC5PFkh\|ryP	NFvq[49USU6JRWK=
LB996-RCC	M37Ocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3rSXlKSzVyPUCuNFA6QTFizszN	NXHPPJcyW0GQR1XS
SW982	NFO4S45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPaTWM2OD1yLkCxNVE2KM7:TR?=	NXL0PW5NW0GQR1XS
TK10	M2TLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnnSWp{UUN3ME2wMlAyOTd2IN88US=>	NFTscnNUSU6JRWK=
A704	M1LQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYG4eG9KUUN3ME2wMlAyPDlzIN88US=>	NIXXWWJUSU6JRWK=
TE-8	NI\yZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2ixRWlEPTB;MD6wNVU4PiEQvF2=	MkPqV2FPT0WU
DOHH-2	NXi2NoJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfnSFVKSzVyPUCuNFE4OTlizszN	M2TpRXNCVkeHUh?=
HOP-62	M3fYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTBwMEG4N\|Qh\|ryP	NF[1OXZUSU6JRWK=
TE-12	NEe5Tm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIn6S5lKSzVyPUCuNFE5PjFizszN	NYLsbZV7W0GQR1XS
KGN	M4DDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEX5eVFKSzVyPUCuNFE6PDJizszN	M2S5RXNCVkeHUh?=
NCI-H1648	Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIKyd2tKSzVyPUCuNFIxOTFizszN	MoXtV2FPT0WU
OS-RC-2	NH3LZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfGTWM2OD1yLkCyNFMh\|ryP	Mmf0V2FPT0WU
GB-1	NHfJTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTBwMEKxOVch\|ryP	MVfTRW5ITVJ?
RXF393	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETw[2lKSzVyPUCuNFI{PTdizszN	MXvTRW5ITVJ?
LC-2-ad	NXGyfWgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPJVotJUUN3ME2wMlAzPTh4IN88US=>	M2r0WHNCVkeHUh?=
KS-1	MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17GbGlEPTB;MD6wNlc{KM7:TR?=	M{D2OHNCVkeHUh?=
ETK-1	Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTBwMEK4N\|Ih\|ryP	MVnTRW5ITVJ?
SW954	NUDZZ\|g{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jpbWlEPTB;MD6wNlkzPyEQvF2=	NHjkd2dUSU6JRWK=
Becker	M{j4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn22TWM2OD1yLkCzNFA{KM7:TR?=	MWDTRW5ITVJ?
MZ1-PC	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jwfWlEPTB;MD6wN\|EyQSEQvF2=	M2rvc3NCVkeHUh?=
ES6	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrLTot{UUN3ME2wMlA{OTl\|IN88US=>	MXjTRW5ITVJ?
KURAMOCHI	NHXFS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjMWXdKSzVyPUCuNFM1QDdizszN	NH6zO2ZUSU6JRWK=
CGTH-W-1	MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XuR2lEPTB;MD6wN\|U1QCEQvF2=	MlTYV2FPT0WU
VA-ES-BJ	M37QfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XlRmlEPTB;MD6wN\|kxOiEQvF2=	M4TjW3NCVkeHUh?=
LXF-289	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzkTWM2OD1yLkCzPVU3KM7:TR?=	NHzaZWpUSU6JRWK=
MPP-89	NYDFS3Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWSwXIJDUUN3ME2wMlA1ODR7IN88US=>	MUjTRW5ITVJ?
SW872	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTufZZtUUN3ME2wMlA1OTZzIN88US=>	M4XPRXNCVkeHUh?=
SNB75	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVL1bYdzUUN3ME2wMlA1PDN3IN88US=>	Ml;QV2FPT0WU
PSN1	MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXP3N5ZwUUN3ME2wMlA1PDd2IN88US=>	M1Hq[3NCVkeHUh?=
LB831-BLC	M{fucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;wbJNKSzVyPUCuNFQ3ODlizszN	MoHYV2FPT0WU
MFH-ino	NXHtOJFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fFXWlEPTB;MD6wOFczPCEQvF2=	MVrTRW5ITVJ?
TGBC24TKB	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LuXmlEPTB;MD6wOFc3OSEQvF2=	MoHhV2FPT0WU
A388	M1GwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzqXXZKSzVyPUCuNFUxQTVizszN	Mn;vV2FPT0WU
BB30-HNC	M2rSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXhTWM2OD1yLkC1OFM4KM7:TR?=	NX\HPXNbW0GQR1XS
GI-ME-N	NVXBOFhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfWVpNPUUN3ME2wMlA3OTF6IN88US=>	NFm0RVVUSU6JRWK=
TGBC1TKB	M3HPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTBwME[xOlQh\|ryP	M1nPUHNCVkeHUh?=
TE-10	M{CyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTBwME[zOVch\|ryP	MUPTRW5ITVJ?
A498	M1HM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVqxfWpwUUN3ME2wMlA4Ojh2IN88US=>	M1;hWXNCVkeHUh?=
TE-11	M1PSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWL4V4tZUUN3ME2wMlA4QDV6IN88US=>	MYHTRW5ITVJ?
BB65-RCC	MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzqcnZKSzVyPUCuNFgzOjdizszN	MkSyV2FPT0WU
C2BBe1	M3PJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TzXWlEPTB;MD6wPFMxQCEQvF2=	M1XtPHNCVkeHUh?=
NCI-H747	NGKyPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTBwMEizOlIh\|ryP	M2PvUnNCVkeHUh?=
IST-MES1	M{XxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHTbIRKSzVyPUCuNFg2PTJizszN	MV7TRW5ITVJ?
KALS-1	NEjZXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrNT3U6UUN3ME2wMlA6PDlizszN	NGP1R5BUSU6JRWK=
GCIY	NHzaOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLveVRKSzVyPUCuNFk3PTZizszN	NE\3WJRUSU6JRWK=
RL95-2	Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTBwMUCzPEDPxE1?	NXfnTo1PW0GQR1XS
TE-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zmPWlEPTB;MD6xNFU1KM7:TR?=	NVHQZXQxW0GQR1XS
NCI-H1355	NUj1clNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTBwMUGwNlgh\|ryP	NWXEWXNzW0GQR1XS
SW962	NV60O2VFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvMfohKSzVyPUCuNVEzQTJizszN	M1GycnNCVkeHUh?=
KLE	NHjiNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXtTWM2OD1yLkGxN\|E4KM7:TR?=	NX;qSopFW0GQR1XS
MC116	MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTBwMUG0NUDPxE1?	Mkn1V2FPT0WU
NMC-G1	MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\MTWM2OD1yLkGxOlA3KM7:TR?=	NUDBWVJUW0GQR1XS
KU812	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\5fYZKSzVyPUCuNVE5QDNizszN	M{TUdnNCVkeHUh?=
COLO-829	NVLq[YdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUi0WnJpUUN3ME2wMlEzOjF\|IN88US=>	NFy0S4hUSU6JRWK=
NTERA-S-cl-D1	NVjxW5RXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HTVmlEPTB;MD6xNlI5OyEQvF2=	M2fW[XNCVkeHUh?=
IST-MEL1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIP2b4RKSzVyPUCuNVM1PSEQvF2=	MlLMV2FPT0WU
MLMA	MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEOyZmpKSzVyPUCuNVQxOzJizszN	MnyyV2FPT0WU
LS-123	MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\EbWlEPTB;MD6xOFA3PCEQvF2=	M2r2ZXNCVkeHUh?=
LB2518-MEL	M3vYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXOO4xKSzVyPUCuNVQyPjJizszN	NEHrS25USU6JRWK=
NB69	NYn1bXQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjiTWM2OD1yLkG0OFM3KM7:TR?=	NVXKdFNDW0GQR1XS
8-MG-BA	M3vZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2G3UWlEPTB;MD6xOVQ2QCEQvF2=	NVTIXFRZW0GQR1XS
K5	NFH5THZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHDbVFKSzVyPUCuNVY1QDlizszN	MWXTRW5ITVJ?
KINGS-1	M4rzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTBwMU[2OlYh\|ryP	NV;NWFJ1W0GQR1XS
SF268	NYj4XJozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHUb5pMUUN3ME2wMlE4PDB2IN88US=>	NFrxNlZUSU6JRWK=
PF-382	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfKdoUxUUN3ME2wMlE4Pjd6IN88US=>	Mn:3V2FPT0WU
SH-4	NWiwR2ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTBwMUi0NVMh\|ryP	M4DaXnNCVkeHUh?=
NALM-6	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPhTWM2OD1yLkG5Nlk2KM7:TR?=	MYXTRW5ITVJ?
CP66-MEL	Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTBwMUm1N\|Eh\|ryP	NH;0UYpUSU6JRWK=
697	NHXKZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIL6bWhKSzVyPUCuNVk6QDdizszN	MmrIV2FPT0WU
CP67-MEL	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\5PJdKSzVyPUCuNlA1QDhizszN	NEXFOHRUSU6JRWK=
DSH1	NV\IdmZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTBwMkSwNFEh\|ryP	MX7TRW5ITVJ?
HCE-4	NF;wSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIW5c5dKSzVyPUCuNlY1OzlizszN	MmDYV2FPT0WU
MZ2-MEL	M3LlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXuO49KSzVyPUCuNlg2OzdizszN	M4LGeXNCVkeHUh?=
BL-41	NXHzdXBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;vWWR2UUN3ME2wMlI6OTJ\|IN88US=>	NIn4VVVUSU6JRWK=
HUTU-80	NXfSV2JtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLVUXIyUUN3ME2wMlMyPDJizszN	NGjMZYhUSU6JRWK=
LOXIMVI	NX3BZXlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\PSmlEPTB;MD6zNVUxOyEQvF2=	M1vldXNCVkeHUh?=
no-10	NGfQOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTBwM{G5N\|Eh\|ryP	NELhWYhUSU6JRWK=
KARPAS-422	MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDPdplPUUN3ME2wMlM{QTl5IN88US=>	MlHEV2FPT0WU
SW684	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fvZWlEPTB;MD6zOFk5KM7:TR?=	M1zpUXNCVkeHUh?=
SF126	M{joV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3Xu[GlEPTB;MD6zOVQyKM7:TR?=	M3PrcXNCVkeHUh?=
D-263MG	MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\LTWM2OD1yLkO2NlI1KM7:TR?=	MoTOV2FPT0WU
OVCAR-4	MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTBwM{e0N\|Mh\|ryP	MUjTRW5ITVJ?
BB49-HNC	MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTBwM{i1PVkh\|ryP	NHG4VYhUSU6JRWK=
ONS-76	NYfzOJNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFz0NGVKSzVyPUCuOFI6PTFizszN	NFfuWHBUSU6JRWK=
MZ7-mel	Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPWRndLUUN3ME2wMlQ4QTFzIN88US=>	M{nWOXNCVkeHUh?=
RCC10RGB	NHrLV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\6TWM2OD1yLkS5NVEh\|ryP	MnS2V2FPT0WU
BOKU	NX;4NGZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrnb4xKSzVyPUCuOFkyOzNizszN	MlvxV2FPT0WU
no-11	M3HiR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnjO3hKSzVyPUCuOVAzOjhizszN	NXK0dIxNW0GQR1XS
IST-SL2	NUT6W24xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn[2TWM2OD1yLkWwN\|AzKM7:TR?=	NH3Y[I9USU6JRWK=
RKO	NEXEcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnUTWM2OD1yLkWyPVY3KM7:TR?=	NEPSTVFUSU6JRWK=
HT-144	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HC[WlEPTB;MD61N\|YxQSEQvF2=	MnP5V2FPT0WU
NCI-H446	NHLmOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1Kz[GlEPTB;MD62Nlc3KM7:TR?=	M1PUTXNCVkeHUh?=
QIMR-WIL	M3vPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnMUIRKSzVyPUCuO\|A3OjlizszN	MX\TRW5ITVJ?
MHH-PREB-1	NVXYe3N3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn:3TWM2OD1yLke0OFY6KM7:TR?=	NHTIdGZUSU6JRWK=
EW-16	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPqTWM2OD1yLke2NVc5KM7:TR?=	M2\2PXNCVkeHUh?=
EW-24	Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml[1TWM2OD1yLke4NVY2KM7:TR?=	M2HOZ3NCVkeHUh?=
LB373-MEL-D	NWnlbYFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTBwOEK1NFgh\|ryP	NGXxeIdUSU6JRWK=
TE-9	MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7kb\|FKSzVyPUCuPFc2OzJizszN	M1P6fXNCVkeHUh?=
A3-KAW	NVr4bJlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInYdndKSzVyPUCuPVg1PTJizszN	MnKwV2FPT0WU
A101D	Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrJb5FvUUN3ME2xMlA{ODR\|IN88US=>	NGr2Uo5USU6JRWK=
OCUB-M	Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jJ[WlEPTB;MT6wOFQyOiEQvF2=	MkjHV2FPT0WU
ES4	M4TZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mke4TWM2OD1zLkC1NVQ2KM7:TR?=	MnnPV2FPT0WU
TE-6	NVTadGl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmCwTWM2OD1zLkKxNlI3KM7:TR?=	M2TiWHNCVkeHUh?=
D-502MG	MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFi0O4hKSzVyPUGuNlM{PzZizszN	MXPTRW5ITVJ?
KNS-42	NF;y[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTFwMkS0NVIh\|ryP	Mmr0V2FPT0WU
SNU-C2B	NYXRXVlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\Cb5pKSzVyPUGuN\|A2QDlizszN	NXLFS5hpW0GQR1XS
NCI-H1838	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DEb2lEPTB;MT6zNFc{OyEQvF2=	MVjTRW5ITVJ?
NKM-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjzS4RwUUN3ME2xMlMxQDV7IN88US=>	MlXxV2FPT0WU
GI-1	MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3sbI5KSzVyPUGuN\|YzOiEQvF2=	MYDTRW5ITVJ?
NB5	M{GzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrBT5YzUUN3ME2xMlM6QDJ5IN88US=>	NEDYR4RUSU6JRWK=
CAS-1	NIjFdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHDd2pKSzVyPUGuOFA6QTJizszN	NHO0U2ZUSU6JRWK=
HCE-T	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vjOWlEPTB;MT61OlcyPCEQvF2=	NHfl[HhUSU6JRWK=
SBC-1	NVHZV\|hDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\rZWpVUUN3ME2xMlU4QTh2IN88US=>	MXvTRW5ITVJ?
JiyoyeP-2003	NF:y[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HWNWlEPTB;MT63N\|Q3PiEQvF2=	NGfhZ5JUSU6JRWK=
TE-5	MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37sVWlEPTB;MT63PVE{QSEQvF2=	NIL4SpFUSU6JRWK=
CAN	M2rwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\BTWM2OD1zLkiyNlUzKM7:TR?=	MofmV2FPT0WU
SK-UT-1	M3vuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLuTWM2OD1{LkG2Olk{KM7:TR?=	NYHnN2V2W0GQR1XS
JVM-2	M2PDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHrTWM2OD1{LkO2Nlg1KM7:TR?=	M2fnWHNCVkeHUh?=
LB771-HNC	M3;tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTSTWM2OD1{LkW3OVUyKM7:TR?=	MVjTRW5ITVJ?
NCCIT	NILsXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTJwOE[2NVYh\|ryP	M13wSHNCVkeHUh?=
NCI-H2126	M3PlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3PT4JKSzVyPUKuPFc2PTJizszN	NHTuXJlUSU6JRWK=
Calu-6	MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPCUGtyUUN3ME2zMlA2PzRzIN88US=>	M1v0N3NCVkeHUh?=
SK-LMS-1	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PoSmlEPTB;Mz6xNVg5PiEQvF2=	NHj6V\|BUSU6JRWK=
ARH-77	M3iwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHf4bWNKSzVyPUOuOFY6OTVizszN	NHTQO2RUSU6JRWK=
NB17	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3j2ZmlEPTB;Mz62N\|g1PyEQvF2=	MorQV2FPT0WU
A253	M3e1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XIemlEPTB;Mz63N\|I1PiEQvF2=	MlHIV2FPT0WU
OPM-2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\X[ZVwUUN3ME20MlI4Pjh3IN88US=>	M{HTV3NCVkeHUh?=
MV-4-11	NECy[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTRwM{[0OVQh\|ryP	M3\CdnNCVkeHUh?=
SR	NYXMSHZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTRwNEm5OVQh\|ryP	Mnn4V2FPT0WU
KG-1	NWHue4dNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfoV41lUUN3ME20MlYxQDR3IN88US=>	NVvkRXJKW0GQR1XS
OCI-AML2	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXqTWM2OD13Lki2NVU1KM7:TR?=	NI\aPJpUSU6JRWK=
D-247MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3x[G9KSzVyPU[uNVI2OTlizszN	NFrPS29USU6JRWK=
DJM-1	NUTXbHZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nHRWlEPTB;Nj60PFU2QCEQvF2=	NULxS3M1W0GQR1XS
RPMI-6666	M3;vZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTdwMkewOlch\|ryP	M3y3NnNCVkeHUh?=
KARPAS-45	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrlZotnUUN3ME23MlUyPjdzIN88US=>	Mn22V2FPT0WU
LP-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zpNWlEPTB;Nz61OFc5OiEQvF2=	MkGzV2FPT0WU
RS4-11	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XaS2lEPTB;Nz62OVc5PyEQvF2=	NXTJcIVbW0GQR1XS
DU-4475	M1XjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;0T2E2UUN3ME24MlIyPjV{IN88US=>	MnTGV2FPT0WU
MONO-MAC-6	NUPKb4hOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3QR2JKSzVyPUiuNlcxPjZizszN	NEPBeHZUSU6JRWK=
NCI-SNU-16	NGHxVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jEcWlEPTB;OD61OlEzQCEQvF2=	NGe0SYJUSU6JRWK=
SJSA-1	NFmzOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\COHhKSzVyPUiuO\|I5ODVizszN	NEPTfndUSU6JRWK=
MMAC-SF	NWPaUWlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\INWlEPTB;OD63PVMxPyEQvF2=	NHnkO\|ZUSU6JRWK=
SK-NEP-1	M{G0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYOzVlRoUUN3ME24Mlg6OTV3IN88US=>	NWS0dmhSW0GQR1XS
J-RT3-T3-5	MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWS2NpRsUUN3ME24Mlk3PTJ7IN88US=>	NITWTG1USU6JRWK=
SKM-1	MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mof6TWM2OD17LkCxO\|M1KM7:TR?=	NEP2OlJUSU6JRWK=
LB2241-RCC	NGTWXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTlwMEKwNVIh\|ryP	MWrTRW5ITVJ?
SIG-M5	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XMcGlEPTB;OT6wNlQ6OyEQvF2=	M1\4eXNCVkeHUh?=
EVSA-T	Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nNfmlEPTB;OT6yO\|c6OyEQvF2=	NGr1[pFUSU6JRWK=
GT3TKB	NY\BT3VCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTlwM{W1OFYh\|ryP	MlPuV2FPT0WU
NB6	M1jv[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TiRWlEPTB;OT65NlI2QSEQvF2=	NIjTW3VUSU6JRWK=
EHEB	M2fBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;MdWpNUUN3ME2xNE4xPjV4IN88US=>	MVvTRW5ITVJ?
HEL	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUftSoVOUUN3ME2xNE41Pzd4IN88US=>	Mnq0V2FPT0WU
ALL-PO	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTFyLke5N\|gh\|ryP	NUHhXndXW0GQR1XS
TGW	NYG3S5BJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPZd5JKSzVyPUGxMlI5OjhizszN	NVHKdpVlW0GQR1XS
BC-3	NVPLV3VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVz6U\|BbUUN3ME2xNk4yOTN6IN88US=>	NYjVbpE4W0GQR1XS
IA-LM	NGjHZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjkbXRKSzVyPUGyMlQ1PDVizszN	M2jHVnNCVkeHUh?=
UACC-257	NG\EV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7HSXhKSzVyPUGyMlkyQThizszN	MYnTRW5ITVJ?
KP-N-YS	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnCTWM2OD1zMj65Nlg{KM7:TR?=	NFW4cJBUSU6JRWK=
Raji	M1\sTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LPemlEPTB;MUOuO\|Q6PyEQvF2=	M1LFdnNCVkeHUh?=
SF539	NF7hS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTF\|Lki1OVch\|ryP	NF7GdnNUSU6JRWK=
DMS-153	M1e4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXK1SGJWUUN3ME2xOE4xODJ6IN88US=>	NXm2SG5kW0GQR1XS
L-540	NWPmfZg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfacm5KSzVyPUG1MlA3PzJizszN	M4D6U3NCVkeHUh?=
MN-60	M3;VNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTF3LkG5O\|kh\|ryP	NIn3Om9USU6JRWK=
RPMI-8866	M{P6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nJUWlEPTB;MUeuOFQ2PCEQvF2=	MofZV2FPT0WU
NCI-H510A	NHTXd2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\Kfo1HUUN3ME2xPU4{QTd\|IN88US=>	NHX4N2RUSU6JRWK=
NB13	NF\BTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkiwTWM2OD1zOT60PFc4KM7:TR?=	MVHTRW5ITVJ?
HAL-01	Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LaUmlEPTB;MUmuO\|U1OyEQvF2=	NYPJPIhUW0GQR1XS
NCI-H720	NUTtT5g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY[zPY5ZUUN3ME2yNE4zPzN\|IN88US=>	NGHsZXJUSU6JRWK=
REH	NFz6bVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTJyLk[zOVch\|ryP	M3PkOXNCVkeHUh?=
KNS-81-FD	M{DNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTwXm9UUUN3ME2yN{4yPDZizszN	M3fq[XNCVkeHUh?=
HC-1	Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTJ2LkW1OVEh\|ryP	Ml7XV2FPT0WU
NCI-H2141	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTJ2Lke3OVQh\|ryP	Ml60V2FPT0WU
MOLT-4	NE\iOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXsTWM2OD1{Nj62O\|U{KM7:TR?=	MXjTRW5ITVJ?
OMC-1	NH;5bnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\1fJFKSzVyPUK3MlE1OjJizszN	NH3EVo9USU6JRWK=
LC-1F	NH\VdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2ThNGlEPTB;MkeuN\|I1PSEQvF2=	NETMe\|VUSU6JRWK=
NCI-H1304	M2e0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWC0SYlOUUN3ME2yPE4yPjJ6IN88US=>	MVHTRW5ITVJ?
BC-1	NHjFeYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoT6TWM2OD1{OD62OVEh\|ryP	NVvEenJLW0GQR1XS
NCI-H64	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIS3NGFKSzVyPUK5MlYzPTNizszN	NV3RUopZW0GQR1XS
MOLT-16	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTJ7Lk[yPVIh\|ryP	M3;jdnNCVkeHUh?=
U-87-MG	NWjNZodPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHKNVFKSzVyPUOwMlc3PiEQvF2=	NFS4TYJUSU6JRWK=
GAK	NWDIW4xrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH6zV4VKSzVyPUOxMlI3QDZizszN	MVfTRW5ITVJ?
ES8	NVriPWFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LFTmlEPTB;M{KuNVI2OiEQvF2=	NGfFPWFUSU6JRWK=
HCC1599	NETHPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHkTWM2OD1\|Mj6zN\|I2KM7:TR?=	MVjTRW5ITVJ?
EB-3	NYDHWpNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTN2LkOxNVch\|ryP	Ml7sV2FPT0WU
HCC1187	MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTN3LkiwOVIh\|ryP	NUiyW\|RKW0GQR1XS
SK-PN-DW	NVHIWJJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUC5Nlk5UUN3ME2zOk4yQTR\|IN88US=>	MkLUV2FPT0WU
JVM-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDUTWM2OD1\|Nz6yN\|M5KM7:TR?=	M2jFcnNCVkeHUh?=
HCC2157	Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTN5Lkm5OFYh\|ryP	MXvTRW5ITVJ?
A4-Fuk	NVPKfpFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPsZphKSzVyPUO4MlExODlizszN	M1XxeHNCVkeHUh?=
COR-L279	M1PMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDLTWM2OD12MD6yPFUyKM7:TR?=	NFr3b3JUSU6JRWK=
DEL	NFHhOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofKTWM2OD12MT65NFg3KM7:TR?=	NFj3VlFUSU6JRWK=
NCI-H1395	NWXheplwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjPTWM2OD12Mj6wNVY{KM7:TR?=	NFf4dHhUSU6JRWK=
MHH-NB-11	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\QTWM2OD12Mz6wPFE5KM7:TR?=	M3TZWXNCVkeHUh?=
NCI-H2107	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTlSIJlUUN3ME20N{41QDR4IN88US=>	M2[wSnNCVkeHUh?=
NEC8	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXkdXpKSzVyPUS0MlM{PiEQvF2=	MlS4V2FPT0WU
COLO-684	NVHnRo5RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17KVGlEPTB;NE[uNlI2QCEQvF2=	NFTPNllUSU6JRWK=
LS-411N	NWTyT5VwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPETWM2OD12OD60O\|Q5KM7:TR?=	NWTs[nc5W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

In vivo

Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. ^[3]

Protocol

Kinase Assay: ^[1]	+ Expand Kinase autophosphorylation assays: Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research: ^[1]	+ Expand Cell lines: Ba/F3 cell lines Concentrations: ~32 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I. (Only for Reference)
Animal Research: ^[3]	+ Expand Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC) Formulation: DMSO Dosages: 30 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

+ Expand

Solubility (25°C)

In vitro	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dasatinib SDF

Molecular Weight	488.01
Formula	C₂₂H₂₆ClN₇O₂S
CAS No.	302962-49-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	BMS-354825

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04063124	Not yet recruiting	Drug: Dasatinib + Quercetin	Alzheimer Disease	The University of Texas Health Science Center at San Antonio\|Mayo Clinic	December 2019	Phase 1\|Phase 2
NCT04115059	Not yet recruiting	Drug: Dasatinib	Waldenstrom Macroglobulinemia\|DASATINIB	Jorge J. Castillo MD\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute	November 2019	Phase 1
NCT03318770	Not yet recruiting	Drug: Dasatinib and blinatumomab	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--
NCT03625388	Recruiting	Drug: Dasatinib	Chronic Myelogenous Leukemia	Hikma Pharmaceuticals LLC	November 5 2018	Phase 2
NCT03193281	Recruiting	Drug: Dasatinib\|Drug: Imatinib	Chronic Myeloid Leukemia	University of Auckland New Zealand\|Leukaemia & Blood Cancer New Zealand	July 17 2017	Phase 2
NCT03041701	Recruiting	Drug: Dasatinib\|Drug: Ganitumab	Rhabdomyosarcoma\|Rhabdomyosarcoma- Alveolar\|Rhabdomyosarcoma-Embryonal	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	July 7 2017	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?
Answer:
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).
Question 2:
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?
Answer:
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Pan Src Inhibitor

Saracatinib (AZD0530) : Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.
FDA-approved Src Inhibitor

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
Newest Src Inhibitor

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
Classic Src Inhibitor

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Related Src Products

Dasatinib Monohydrate ^New

Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Bosutinib (SKI-606)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
KX2-391

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib

Cited by 138 Publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dasatinib SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib

Cited by 138 Publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dasatinib SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)